About us


Naoki Tarui, Ph.D.
CEO
Dr. Tarui has been involved in drug discovery research especially hit finding for 20 years at Takeda Pharmaceutical Company. A typical hit compound is the seed compound of vonoprazan (the world's first potassium competitive acid blocker).
Dr. Tarui has established SEEDSUPPLY as spin-out from Takeda in 2017 to improve the early drug discovery process for small molecule drugs by using binder selection technology.
Dr. Tarui has advocated a groundbreaking drug discovery that leverages the binder collection.

Management Team

CTO Takashi Motoyaji
VP, BD Yuko Amizaki
Head of Protein Science Takashi Ito